257 related articles for article (PubMed ID: 30931962)
1. Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer.
Ozeki T; Nagahama M; Fujita K; Suzuki A; Sugino K; Ito K; Miura M
Sci Rep; 2019 Apr; 9(1):5404. PubMed ID: 30931962
[TBL] [Abstract][Full Text] [Related]
2. Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia.
Abumiya M; Mita A; Takahashi S; Yoshioka T; Kameoka Y; Takahashi N; Miura M
Med Oncol; 2018 May; 35(6):90. PubMed ID: 29736778
[TBL] [Abstract][Full Text] [Related]
3. Influences of ABC transporter and CYP3A4/5 genetic polymorphisms on the pharmacokinetics of lenvatinib in Chinese healthy subjects.
Li J; Wang X; Ning C; Wang Z; Wang Y; Zheng M; Zhang S; Lu Y; Zhang Y; Li N; Chen X; Zhao D
Eur J Clin Pharmacol; 2020 Aug; 76(8):1125-1133. PubMed ID: 32382947
[TBL] [Abstract][Full Text] [Related]
4. Association between pharmacokinetics of lenvatinib in healthy subjects and genetic polymorphisms of
Song H; Bai W; Sun X; Qiu B; Guo N; Guo C; Hu Y; Dong Z
Xenobiotica; 2021 Dec; 51(12):1463-1469. PubMed ID: 34979850
[TBL] [Abstract][Full Text] [Related]
5. Impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of lenvatinib in patients with hepatocellular carcinoma.
Okubo H; Ando H; Ishizuka K; Morishige JI; Ikejima K; Shiina S; Nagahara A
J Pharmacol Sci; 2022 Jan; 148(1):6-13. PubMed ID: 34924131
[TBL] [Abstract][Full Text] [Related]
6. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
[TBL] [Abstract][Full Text] [Related]
8. Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer.
Nagahama M; Ozeki T; Suzuki A; Sugino K; Niioka T; Ito K; Miura M
Med Oncol; 2019 Mar; 36(5):39. PubMed ID: 30919115
[TBL] [Abstract][Full Text] [Related]
9. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.
Cho JH; Yoon YD; Park JY; Song EJ; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
Transplant Proc; 2012 Jan; 44(1):109-14. PubMed ID: 22310591
[TBL] [Abstract][Full Text] [Related]
10. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
Chew SC; Singh O; Chen X; Ramasamy RD; Kulkarni T; Lee EJ; Tan EH; Lim WT; Chowbay B
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1471-8. PubMed ID: 21468756
[TBL] [Abstract][Full Text] [Related]
11. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
Tsai SM; Lin CY; Wu SH; Hou LA; Ma H; Tsai LY; Hou MF
Clin Chim Acta; 2009 Jun; 404(2):160-5. PubMed ID: 19332043
[TBL] [Abstract][Full Text] [Related]
12. Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer.
Yokota H; Sato K; Sakamoto S; Okuda Y; Fukuda N; Asano M; Takeda M; Nakayama K; Miura M
Invest New Drugs; 2022 Dec; 40(6):1254-1262. PubMed ID: 36149549
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients.
Provenzani A; Notarbartolo M; Labbozzetta M; Poma P; Vizzini G; Salis P; Caccamo C; Bertani T; Palazzo U; Polidori P; Gridelli B; D'Alessandro N
Int J Mol Med; 2011 Dec; 28(6):1093-102. PubMed ID: 21922127
[TBL] [Abstract][Full Text] [Related]
14. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
Yoon SH; Cho JH; Kwon O; Choi JY; Park SH; Kim YL; Yoon YR; Won DI; Kim CD
Transplantation; 2013 Mar; 95(6):828-34. PubMed ID: 23364483
[TBL] [Abstract][Full Text] [Related]
15. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):320-326. PubMed ID: 29603629
[TBL] [Abstract][Full Text] [Related]
16. Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China.
Meng XG; Guo CX; Feng GQ; Zhao YC; Zhou BT; Han JL; Chen X; Shi Y; Shi HY; Yin JY; Peng XD; Pei Q; Zhang W; Wang G; He M; Liu M; Yang JK; Zhou HH
Acta Pharmacol Sin; 2012 Dec; 33(12):1563-70. PubMed ID: 23085740
[TBL] [Abstract][Full Text] [Related]
17. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
[TBL] [Abstract][Full Text] [Related]
18. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation.
Ueshima S; Hira D; Fujii R; Kimura Y; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Horie M; Terada T; Katsura T
Pharmacogenet Genomics; 2017 Sep; 27(9):329-336. PubMed ID: 28678049
[TBL] [Abstract][Full Text] [Related]
19. ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone.
Ganoci L; Trkulja V; Živković M; Božina T; Šagud M; Lovrić M; Božina N
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110042. PubMed ID: 32682874
[TBL] [Abstract][Full Text] [Related]
20. Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation.
Nakagawa J; Kinjo T; Iizuka M; Ueno K; Tomita H; Niioka T
Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):297-304. PubMed ID: 32920985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
